GH vs. MRNA

In the year-to-date period, GH achieves a 60.39% return, which is significantly higher than MRNA's -13.66% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Guardant Health, Inc. (GH) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current GH Sharpe Ratio is 1.81, which is higher than the MRNA Sharpe Ratio of -0.92. The chart below compares the historical Sharpe Ratios of GH and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither GH nor MRNA has paid dividends to shareholders.

The maximum GH drawdown since its inception was -91.03%, roughly equal to the maximum MRNA drawdown of -93.70%. Use the drawdown chart below to compare losses from any high point for GH and MRNA. For additional features, visit the drawdowns tool.

Guardant Health, Inc. (GH) and Moderna, Inc. (MRNA) have volatilities of 24.32% and 24.89%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Guardant Health, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.